Brazil’s Health Regulatory Agency (Anvisa) has granted Brazilian Agricultural Research Corporation (Embrapa) an exceptional authorization to conduct scientific research on cannabis cultivation.

The authorization is strictly limited to research purposes and does not permit any form of commercialization.

According to Embrapa, the measure will help establish a national scientific foundation on cannabis, decrease dependence on imported inputs, and support future regulatory decisions. The approval comes shortly after more than BRL 13 million were allocated to CBD-related research.

Before the studies begin, Embrapa must undergo an on-site inspection and comply with strict security and control requirements. Anvisa will monitor the entire process. No products resulting from the research may be sold, and plant material may only be shared with previously authorized research institutions.

Embrapa’s research will focus on three areas: conservation and characterization of germplasm, scientific and technological bases for medicinal cannabis, and pre-breeding of hemp for fiber and seed production.

The institution states that the authorization represents a significant step as global interest in cannabis grows, highlighting its economic, social, and medicinal potential.